Skip to main content
SpringerLink
Log in

Effects of Ginkgo biloba Extract EGb 761® on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial

Effekte von Ginkgo-Spezialextract EGb 761® auf neuropsychiatrische Symptome der Demenz: Ergebnisse einer randomisierten kontrollierten Studie

  • Themenschwerpunkt
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

In einer 22-wöchigen, randomisierten Doppelblindstudie wurden 400 Patienten, die an einer Demenz mit neuropsychiatrischen Symptomen litten, mit Ginkgo-biloba-Extrakt EGb 761® (240 mg/die) behandelt oder erhielten Placebo. Patienten mit wahrscheinlicher Alzheimer-Krankheit, möglicher Alzheimer-Krankheit mit cerebrovaskulärer Erkrankung oder wahrscheinlicher vaskulärer Demenz wurden eingeschlossen, wenn sie Werte zwischen 9 und 23 im Syndrom-Kurztest (SKT) und mindestens 5 Punkte im Neuropsychiatrischen Inventar (NPI) aufwiesen. EGb 761® zeigte signifikant bessere Ergebnisse als Placebo in der Zielgröße (SKT) und allen Begleitgrößen. Der mittlere zusammengesetzte Skalenwert (Häufigkeit × Schwere) des NPI und der mittlere Wert für die Belastung der Betreuungsperson fiel unter EGb 761® von 21,3 auf 14,7 bzw. von 13,5 auf 8,7. Hingegen nahmen die entsprechenden Werte unter Placebo von 21,6 auf 24,1 bzw. von 13,4 auf 13,9 zu (p < 0.001). Die größten Verum-Placebo-Differenzen zugunsten von EGb 761® fanden sich für Apathie/Gleichgültigkeit, Angst, Reizbarkeit/Labilität, Depression/Dysphorie und Schlafstörungen/nächtliches Verhalten.

Summary

In a randomised, double-blind, 22-week trial 400 patients with dementia associated with neuropsychiatric features were treated with Ginkgo biloba extract EGb 761® (240 mg/day) or placebo. Patients with probable Alzheimer's disease, possible Alzheimer's disease with cerebrovascular disease or vascular dementia were eligible if they scored 9 to 23 on the SKT cognitive test battery and at least 5 on the Neuropsychiatric Inventory (NPI). EGb 761® was significantly superior to placebo with respect to the primary (SKT test battery) and all secondary outcome variables. The mean composite score (frequency × severity) and the mean caregiver distress score of the NPI dropped from 21.3 to 14.7 and 13.5 to 8.7, respectively, in the EGb 761®-treated patients, but increased from 21.6 to 24.1 and 13.4 to 13.9, respectively, under placebo (p < 0.001). The largest drug-placebo differences in favour of EGb 761® were found for apathy/indifference, anxiety, irritability/lability, depression/dysphoria and sleep/nighttime behaviour.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS (2000) Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157: 708–714

    Article  PubMed  CAS  Google Scholar 

  • Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky ST (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. Results from the Cardiovascular Health Study. JAMA 288: 1475–1483

    Article  PubMed  Google Scholar 

  • Chan DC, Kasper JD, Black BS, Rabins PV (2003) Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. Int J Geriatr Psychiatry 18: 174–182

    Article  PubMed  Google Scholar 

  • Cummings JL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48(Suppl 6): S10–S16

    PubMed  CAS  Google Scholar 

  • Alzheimer A (1906) Über einen eigenartigen schweren Erkrankungsprozess der Hirnrinde. Neurologisches Centralblatt 23: 1129–1136

    Google Scholar 

  • Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, MacMillan A, Ketchel P, DeKosky ST (1998) Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 46: 210–215

    PubMed  CAS  Google Scholar 

  • Snow AL, Dani R, Souchek J, Sullivan G, Ashton CM, Kunik ME (2005) Comorbid psychosocial symptoms and quality of life in patients with dementia. Am J Geriatr Psychiatry 13: 393–401

    Article  PubMed  Google Scholar 

  • Jönsson L, Jönhagen ME, Kilander L, Soininen H, Hallikainen M, Waldemar G, Nygaard H, Andreasen N, Winblad B, Wimo A (2006) Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 21: 449–459

    Article  PubMed  Google Scholar 

  • Juva K, Mäkelä M, Sulkava R, Erkinjuntti T (1997) One-year risk of institutionalization in demented outpatients with caretaking relatives. Int Psychogeriatr 9: 175–182

    Article  PubMed  CAS  Google Scholar 

  • Gilley DW, Bienias JL, Wilson RS, Bennett DA, Beck TL, Evans DA (2004) Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychol Med 34: 1129–1135

    Article  PubMed  CAS  Google Scholar 

  • de Vugt ME, Stevens F, Aalten P, Lousberg R, Jaspers N, Verhey FRJ (2005) A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. Int Psychogeriatr 17: 1–13

    Article  Google Scholar 

  • Ernst E, Pittler MH (2005) Ginkgo biloba for vascular dementia and Alzheimer's disease: updated systematic review of double-blind, placebo-controlled, randomized trials. Perfusion 18: 388–392

    Google Scholar 

  • Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M (2005) A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2: 541–551

    Article  PubMed  CAS  Google Scholar 

  • Hoerr R (2003) Behavioural and psychological symptoms of dementia (BPSD): Effects of EGb 761®. Pharmacopsychiatry 36 (Suppl 1): S56–S61

    PubMed  CAS  Google Scholar 

  • Ramassamy C, Christen Y, Clostre F, Costentin J (1992) The Ginkgo biloba extract, EGb 761, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. J Pharm Pharmacol 44: 943–945

    PubMed  CAS  Google Scholar 

  • Rapin JR, Lamproglou I, Drieu K, DeFeudis FV (1994) Demonstration of the "anti-stress" activity of an extract of Ginkgo biloba (EGb 761) using a discrimination learning task. Gen Pharmacol 25: 1009–1016

    PubMed  CAS  Google Scholar 

  • Marcilhac A, Dakine N, Bourhim N, Guillaume V, Grino M, Drieu K, Oliver C (1998) Effect of chronic administration of Ginkgo biloba extract or ginkgolide on the hypothalamic-pituitary-adrenal axis in the rat. Life Sci 62: 2329–2340

    Article  PubMed  CAS  Google Scholar 

  • Jezova D, Duncko R, Lassanova M, Kriska M, Moncek F (2002) Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761®) in healthy volunteers. J Physiol Pharmacol 53: 337–348

    PubMed  CAS  Google Scholar 

  • Hoyer S, Lannert H, Nöldner M, Chatterjee SS (1999) Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 106: 1171–1188

    Article  PubMed  CAS  Google Scholar 

  • Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P (2002) Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb 761. Proc Natl Acad Sci USA 99: 12197–12202

    Article  PubMed  CAS  Google Scholar 

  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH (1996) Good Clinical Practice: Consolidated Guideline. ICH, Geneva

    Google Scholar 

  • Napryeyenko O, Borzenko I, for the GINDEM-NP Study Group (2007) Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneim Forsch / Drug Res 57: 4–11

    CAS  Google Scholar 

  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944

    PubMed  CAS  Google Scholar 

  • Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O'Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau AK, Bell MA, DeCarli C, Culebras A, Korczyn AD, Bogousslavsky J, Hartmann A, Scheinberg P (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250–260

    PubMed  Google Scholar 

  • Mahoney R, Johnston K, Katona C, Maxmin K, Livingston G (2005) The TE4D-Cog: a new test for detecting early dementia in English-speaking populations. Int J Geriatr Psychiatry 20: 1172–1179

    Article  PubMed  Google Scholar 

  • Kim YS, Nibbelink DW, Overall JE (1993) Factor structure and scoring of the SKT test battery. J Clin Psychol 49: 61–71

    Article  PubMed  CAS  Google Scholar 

  • Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH (1989) Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 37: 725–729

    PubMed  CAS  Google Scholar 

  • Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62

    Article  PubMed  CAS  Google Scholar 

  • Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL (1999) The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56: 1388–1393

    Article  PubMed  CAS  Google Scholar 

  • Shader RI, Harmatz JS, Salzman C (1974) A new scale for clinical assessment on geriatric populations: SANDOZ Clinical Assessment – Geriatric (SCAG). J Am Geriat Soc 22: 107–113

    PubMed  CAS  Google Scholar 

  • Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, and the Galantamine USA-10 Study Group (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54: 2269–2276

    PubMed  CAS  Google Scholar 

  • Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in Alzheimer's disease. Neurology 45: 130–135

    Google Scholar 

  • Rösler M (2002) The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract (Suppl 127): 20–36

  • Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J (2004) The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63: 214–219

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chair of Psychiatry, Poltava Regional Psychiatry Hospital, Poltava, Ukraine

    Andrey Scripnikov

  2. Clinical Research Center of the Schwabe Group, Kyiv, Ukraine

    Alexander Khomenko

  3. Psychiatry Department, National Medical University, Kyiv, Ukraine

    Oleksandr Napryeyenko

Authors
  1. Andrey Scripnikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Khomenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Oleksandr Napryeyenko
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the GINDEM-NP Study Group

Corresponding author

Correspondence to Alexander Khomenko.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scripnikov, A., Khomenko, A., Napryeyenko, O. et al. Effects of Ginkgo biloba Extract EGb 761® on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr 157, 295–300 (2007). https://doi.org/10.1007/s10354-007-0427-5

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-007-0427-5

Schlüsselwörter

Keywords

Search

Navigation